Incremental treatment expenditure of diabetes in the United States

Managed Care Interface

Volumn 20, Issue 4, 2007, Pages 20-27

  Balu, Sanjeev ^a  

^a ABT ASSOCIATES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BIGUANIDE; INSULIN; MEGLITINIDE; SULFONYLUREA;

ARTICLE; COST OF ILLNESS; DEMOGRAPHY; DIABETES MELLITUS; DISEASE CLASSIFICATION; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MEDICAL CARE; POPULATION RESEARCH; PRESCRIPTION; PROBABILITY; REGRESSION ANALYSIS; UNITED STATES;

ADOLESCENT; ADULT; AGED; CHRONIC DISEASE; COST OF ILLNESS; DIABETES MELLITUS; DIRECT SERVICE COSTS; FEMALE; HEALTH EXPENDITURES; HEALTH SERVICES; HUMANS; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MIDDLE AGED; PREVALENCE; UNITED STATES;

EID: 34247378716     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. National diabetes fact sheet, United States, 2005. Centers for Disease Control and Prevention (www.cdc.gov/diabetes/pubs/pdf/ndfs_2005.pdf), February 2007.
2. Wild S, Roglic G, Green A, et al: Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-1053.
3. Harris MI, Flegal KM, Cowie CC, et al: Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in US adults. The Third National Health and Nutrition Examination Survey (NHANES) 1988-1994. Diabetes Care 1998;21:518-524.
4. Stratton IM, Adler AI, Neil HA, et al: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 2000;321:405-412.
5. Brown JB, Pedula KL, Bakst AW: The progressive cost of complications in type 2 diabetes mellitus. Arch Int Med 1999;159: 1873-1880.
6. Menzin J, Langley-Hawthorne C, Friedman M, et al: Potential short-term economic benefits of improved glycemic control: A managed care perspective. Diabetes Care 2001;24:51-55.
7. Wagner EH, Sandhu N, Newton KM, et al: Effect of improved glycemic control on health care costs and utilization. JAMA 2001; 285:182-189.
8. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
9. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
10. Stephens JM, Botteman MF, Hay JW: Economic impact of antidiabetic medications and glycemic control on managed care organizations: A review of the literature. J Manag Care Pharm 2006;12:130-142.
11. Haffner SM, Lehto S, Ronnemaa T, et al: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med 1998;339:229-234.
12. Diabetes facts. American Diabetes Association (www.diabetes.org/home.jsp) , February 2007.
13. Health information. National Eye Institute (www.nei.nih.gov), February 2007.
14. National diabetes information clearing-house. National Institute of Diabetes and Digestive and Kidney Diseases (www.niddk.nih.gov), February 2007.
15. Jonsson L, Bolinder B, Lundkvist J: Cost of hypoglycemia in patients with type 2 diabetes in Sweden. Value Health 2006;9: 193-198.
16. Heaton A, Martin S, Brelje T: The economic effect of hypoglycemia in a health plan. Manag Care Interface 2003;16:23-27.
17. Entmacher PS: Report of Economic Impact of Diabetes. National Institutes of Health publication No. (NIH) 76-1022, Washington, DC, U.S. Department of Health and Human Services, 1976.
18. American Diabetes Association: Economic costs of diabetes in the U.S. in 2002. Diabetes Care 2003;26:917-932.
19. Caro JJ, Ward AJ, O'Brien JA: Lifetime costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 2002;25: 476-481.
20. Ettaro L, Songer TJ, Zhang P, et al: Cost-of-illness studies in diabetes mellitus. Pharmacoeconomics 2004;22:149-164.
21. Rice DP, Cooper BS: The economic value of human life. Am J Public Health 1967;57:1954-1966.
22. Smith DH, Malone DC, Lawson KA, et al: A national estimate of the economic costs of asthma. Am J Respir Crit Care Med 1997; 156:787-793.
23. Qureshi AI, Suri MF, Kirmani JF, et al: The relative impact of primary and secondary prevention on cardiovascular mortality in the United States. Stroke 2004;35:2346-2350.
24. American Diabetes Association: Economic consequences of diabetes mellitus in the U.S. in 1997. Diabetes Care 1998;21: 296-309.
25. Ward MM, Javitz HS, Smith WM, et al: A comparison of three approaches for attributing hospitalizations to specific diseases in cost analyses. Int J Technol Assess Health Care 2000;16:125-136.
26. Martin BC, Ricci JF, Kotzan JA, et al: The net cost of Alzheimer disease and related dementia: A population-based study of Georgia Medicaid recipients. Alzheimer's Dis Assoc Disord 2000;14:151-159.
27. Gabriel SE, Tosteson AN, Liebson CL, et al: Direct medical costs attributable to osteoporotic fractures. Osteoporos Int 2002;13: 323-330.
28. Birnbaum HG, Leong SA, Oster EF, et al: Cost of stress urinary incontinence: A claims data analysis. Pharmacoeconomics 2004;22:95-105.
29. Lee DW, Meyer JW, Clouse J: Implications of controlling for comorbid conditions in cost-of-illness estimates: A case study of osteoarthritis from a managed care system perspective. Value Health 2001;4:329-334.
30. Yelin E, Trupin L, Cisternas M, et al: A national study of medical care expenditures for respiratory conditions. Eur Respir J 2002;19:414-421.
31. Martin BC, Ganguly R, Pannicker S, et al: Utilization patterns and net direct medical cost to Medicaid of irritable bowel syndrome. Curr Med Res Opin 2003;19:771-780.
32. Overview of the MEPS database. Agency for Healthcare Research and Quality (www.ahcpr.gov/data/mepsweb.htm#datapub), February 2007.
33. Duan N: Smearing estimate: A nonparametric retransformation method. J Am Stat Assoc 1983;78:605-610.
34. Russell LB, Valiyeva E, Roman SH, et al: Hospitalizations, nursing home admissions, and deaths attributable to diabetes. Diabetes Care 2005;28:1611-1617.
35. Nichols GA, Glauber HS, Brown JB: Type 2 diabetes: Incremental medical care costs during the 8 years preceding diagnosis. Diabetes Care 2000;23:1654-1659.
36. Ramsey S, Summers KH, Leong SA, et al: Productivity and medical costs of diabetes in a large employer population. Diabetes Care 2002;25:23-29.
37. Selby JV, Ray GT, Zhang D, et al: Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care 1997;20:1396-1402.
38. Guo JJ, Gibson JT, Gropper DM, et al: Empiric investigation on direct costs-of-illness and healthcare utilization of Medicaid patients with diabetes mellitus. Am J Manag Care 1998;4:1433-1446.
39. Maciejewski ML, Maynard C: Diabetes-related utilization and costs for inpatient and outpatient services in the Veterans Administration. Diabetes Care 2004;27(suppl 2):69-73.
40. Jiang HJ, Stryer D, Friedman B, et al: Multiple hospitalizations for patients with diabetes. Diabetes Care 2003;26:1421-1426.
41. Gilmer TP, O'Connor PJ, Rush WA, et al: Predictors of health care costs in adults with diabetes. Diabetes Care 2005;28:59-64.
42. Brandle M, Zhou H, Smith BR, et al: The direct medical cost of type 2 diabetes. Diabetes Care 2003;26:2300-2304.
43. Kamal-Bahl SJ, Pantely S, Pyenson B, et al: Employer-paid nonmedical costs for patients with diabetes and end-stage renal disease. Prev Chronic Dis 2006;3:A83.
44. Romano PS, Mark DH: Bias in the coding of hospital discharge data and its implications for quality assessment. Med Care 1994;32:81-90.